A preoperative package of care for osteoarthritis, consisting of weight loss, orthotics, rehabilitation, and topical and oral analgesia (OPPORTUNITY): a two-centre, open-label, randomised controlled feasibility trial
- PMID: 38423028
- DOI: 10.1016/S2665-9913(23)00337-5
A preoperative package of care for osteoarthritis, consisting of weight loss, orthotics, rehabilitation, and topical and oral analgesia (OPPORTUNITY): a two-centre, open-label, randomised controlled feasibility trial
Abstract
Background: Osteoarthritis of the knee is a major cause of disability worldwide. Non-operative treatments can reduce the morbidity but adherence is poor. We hypothesised that adherence could be optimised if behavioural change was established in the preoperative period. Therefore, we aimed to assess feasibility, acceptability, and recruitment and retention rates of a preoperative package of non-operative care in patients awaiting knee replacement surgery.
Methods: We did an open-label, randomised controlled, feasibility trial in two secondary care centres in the UK. Eligible participants were aged 15-85 years, on the waiting list for a knee arthroplasty for osteoarthritis, and met at least one of the thresholds for one of the four components of the preoperative package of non-operative care intervention (ie, weight loss, exercise therapy, use of insoles, and analgesia adjustment). Participants were randomly assigned (2:1) to either the intervention group or the standard of care (ie, control) group. All four aspects of the intervention were delivered weekly over 12 weeks. Participants in the intervention group were reviewed regularly to assess adherence. The primary outcome was acceptability and feasibility of delivering the intervention, as measured by recruitment rate, retention rate at follow-up review after planned surgery, health-related quality of life, joint-specific scores, and adherence (weight change and qualitative interviews). This study is registered with ISRCTN, ISRCTN96684272.
Findings: Between Sept 3 2018, and Aug 30, 2019, we screened 233 patients, of whom 163 (73%) were excluded and 60 (27%) were randomly assigned to either the intervention group (n=40) or the control group (n=20). 34 (57%) of 60 participants were women, 26 (43%) were men, and the mean age was 66·8 years (SD 8·6). Uptake of the specific intervention components varied: 31 (78%) of 40 had exercise therapy, 28 (70%) weight loss, 22 (55%) analgesia adjustment, and insoles (18 [45%]). Overall median adherence was 94% (IQR 79·5-100). At the final review, the intervention group lost a mean of 11·2 kg (SD 5·6) compared with 1·3 kg (3·8) in the control group (estimated difference -9·8 kg [95% CI -13·4 to -6·3]). A clinically significant improvement in health-related quality o life (mean change 0·078 [SD 0·195]) were reported, and joint-specific scores showed greater improvement in the intervention group than in the control group. No adverse events attributable to the intervention occurred.
Interpretation: Participants adhered well to the non-operative interventions and their health-related quality of life improved. Participant and health professional feedback were extremely positive. These findings support progression to a full-scale effectiveness trial.
Funding: Versus Arthritis.
Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of interests AHRWS is the Data Monitoring Board Chair of ORIF (National Institute for Health and Care Research [NIHR]-funded multicentre study); Steering Committee Chair of PART (NIHR-funded multicentre study); Editor-in-Chief of Bone & Joint Research; and an Editorial Board Member of Bone & Joint Journal. NDC is an Editorial Board Member of Bone & Joint Research and Bone & Joint Journal. SAS is a member of the NIHR Policy Research Panel, Chief Scientist Office (CSO) HIPS Committee, and NIHR/HTA; and has received funding support from the UK Medical Research Council (MRC) and Scottish CSO core funding as part of the MRC/CSO Social and Public Health Sciences Unit Complexity in Health Improvement programme (MC_UU_12017/14, MC_UU_00022/1, SPHSU14, SPHSU16). HP has received grants from NIHR, Zimmer Biomet, DePuy Synthes, Invibio, Allay Therapeutics, and Paradigm Pharma; consulting fees from Medacta International, MicroPort, MAT Ortho, JRI, Smith and Nephew, Invibio, Teleflex, Depuy Synthes, Invibio, Allay Therapeutics, and Paradigm Pharma; expert witness payment for Kennedy's Law; support for travel from Medacta International and Zimmer Biomet; has patents with University of Leeds; is on the Data Safety Monitoring Board for the University of Leeds; and has received equipment or supplies from Pacira Pharmaceuticals. ARL chairs the European industry group: TDMR Europe (the generic industry body that monitors EU legislation and The European Food Safety Authority guidance in relation to total diet replacement food products across Europe). PGC and SRK are supported in part through the NIHR Leeds Biomedical Research Centre. DH has received paid honoraria from Stryker. PC has received core funding from the UK MRC and the Scottish Government CSO for the Informing Healthy Public Policy and Inequalities in Health programmes at the MRC/CSO Social and Public Health Sciences Unit (SPHSU15, SPHSU17, MC_UU_12015/15, MC_UU00022/2). AB-H is an employee and shareholder of Counterweight. JN has received an NIHR/HTA grant to The University of Edinburgh. All other authors declare no competing interests.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous